Literature DB >> 29729449

NLRP3: A promising therapeutic target for autoimmune diseases.

Hui-Hui Shen1, Yue-Xin Yang2, Xiang Meng3, Xiao-Yun Luo1, Xiao-Mei Li4, Zong-Wen Shuai5, Dong-Qing Ye6, Hai-Feng Pan7.   

Abstract

NLRP3, a member of nucleotide-binding domain-(NOD) like receptor family, can be found in large varieties of immune and non-immune cells. Upon activation, the NLRP3, apoptosis-associated speck-like protein (ASC) and pro-caspase-1 would assemble into a multimeric protein, called the NLRP3 inflammasome. Then the inflammasome promotes inflammation (through specific cleavage and production of bioactive IL-1β and IL-18) and pyroptotic cell death. Previous studies have indicated the importance of NLRP3 in regulating innate immunity. Recently, numerous studies have revealed their significance in autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc) and inflammatory bowel disease (IBD). In this review, we will briefly discuss the biological features of NLRP3 and summarize the recent progression of the involvement of NLRP3 in the development and pathogenesis of autoimmune diseases, as well as its clinical implications and therapeutic potential.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Autoimmunity; Inflammasomes; NLRP3

Mesh:

Substances:

Year:  2018        PMID: 29729449     DOI: 10.1016/j.autrev.2018.01.020

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  63 in total

Review 1.  Src Family Protein Kinase Controls the Fate of B Cells in Autoimmune Diseases.

Authors:  Xianzheng Zhang; Dan Mei; Lingling Zhang; Wei Wei
Journal:  Inflammation       Date:  2020-10-10       Impact factor: 4.092

2.  NLRP3 deficiency accelerates pressure overload-induced cardiac remodeling via increased TLR4 expression.

Authors:  Fangfang Li; Hao Zhang; Lu Yang; Hui Yong; Qingqing Qin; Mengtong Tan; Luhong Xu; Kai Liang; Jing Zong; Wenhao Qian
Journal:  J Mol Med (Berl)       Date:  2018-08-29       Impact factor: 4.599

3.  Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity.

Authors:  Hui Wang; Gangduo Wang; Yuejin Liang; Xiaotang Du; Paul J Boor; Jiaren Sun; M Firoze Khan
Journal:  Free Radic Biol Med       Date:  2019-08-13       Impact factor: 7.376

4.  Plasma exosomes derived from patients with intestinal Behçet's syndrome induce intestinal epithelial cell pyroptosis.

Authors:  Cheng-Cheng Hou; Hai-Fen Ma; Jing-Fen Ye; Dan Luo; Hua-Fang Bao; Jian-Long Guan
Journal:  Clin Rheumatol       Date:  2021-05-05       Impact factor: 2.980

Review 5.  The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Winyoo Chowanadisai; Ahmed Bettaieb
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

6.  A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours.

Authors:  Javier Benítez; Roberta Marra; José Reyes; Oriol Calvete
Journal:  Gastric Cancer       Date:  2019-06-27       Impact factor: 7.370

7.  Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors.

Authors:  Sameer Agarwal; Santosh Sasane; Hardik A Shah; Jignesh P Pethani; Prashant Deshmukh; Vismit Vyas; Pravin Iyer; Harsh Bhavsar; Kasinath Viswanathan; Debdutta Bandyopadhyay; Poonam Giri; Jogeswar Mahapatra; Abhijit Chatterjee; Mukul R Jain; Rajiv Sharma
Journal:  ACS Med Chem Lett       Date:  2020-02-27       Impact factor: 4.345

Review 8.  Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.

Authors:  Danbin Wu; Yefei Chen; Yingxin Sun; Qing Gao; Huhu Li; Zhengfei Yang; Yangxue Wang; Xijuan Jiang; Bin Yu
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

9.  Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.

Authors:  Andrew J Kwilasz; Laurel S Todd; Julissa C Duran-Malle; Anouk E W Schrama; Eric H Mitten; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Xiaohui Wang; Anne-Marie Van Dam; Steven F Maier; Kenner C Rice; Linda R Watkins; Ruth M Barrientos
Journal:  Behav Brain Res       Date:  2020-09-06       Impact factor: 3.332

10.  LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macrophage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation.

Authors:  Ziye Wang; Yang Kun; Zhao Lei; Wen Dawei; Pan Lin; Wang Jibo
Journal:  Cell Cycle       Date:  2021-01-18       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.